摘要
目的系统性评价骨瓜提取物促进骨折患者术后修复的有效性和安全性。方法计算机检索PubMed、EMbase、TheCochraneLibrary、CBM、WanFangData和CNKI数据库,检索骨瓜提取物促进骨折患者术后修复的有效性和安全性的RCT试验,检索时限为从建库到2019年1月1日。由2名研究者独立筛选文献,提取资料并评价纳入文献的偏倚风险,最终采用Revman 5.3软件进行Meta分析。结果共纳入13篇RCT研究,1559例研究对象。Meta分析结果表明,与对照组相比,骨瓜提取物组患者的术后功能恢复更好(MD=1.21,95%CI:1.15～1.28,P<0.000 01),术后愈合时间更短(MD=-1.44,95%CI:-2.00～-0.88,P<0.000 01)。此外,骨瓜提取物组患者的疼痛评分更低(MD=-1.49,95%CI:-2.14～-0.84,P<0.00001)。结论当前数据表明,患者骨折术后应用骨瓜提取物能提高功能恢复情况,缩短愈合时间,缓解患者术后疼痛症状,且安全性较好。但是受纳入研究数量与质量的限制,上述结论还需更多高质量研究的验证。
Objective To systematically evaluatereview the efficacy and safety of Gugua(骨瓜)in promoting fracture healing.Methods We electronically searched databases of PubMed,EMbase,the Cochrane Library,CBM,Wan Fang Data and CNKI,from the establishment of the databases to January 1,2019 to find RCTs,which tested the efficacy and safety of Gugua,in improving postoperative recovery of fracture patients.Two researchers independently screened the literature,extracting the data and evaluating the bias risk of the included literature.Eventually,meta analysis was done by Revman 5.3.Results A total of 13 RCTs with 1559 subjects were adopted.Meta analysis showed that patients in Gugua group had better postoperative function than control group(MD=1.21,95%CI:1.15-1.28,P<0.00001),and the healing time is shorter(MD=-1.44,95%CI:-2.00 to-0.88,P<0.00001).In addition,the pain score of patients in Gugua group was lower(MD=-1.49,95%CI:-2.14 to-0.84,P<0.00001).Conclusion Current data showed that the application of cucumis polypeptid extract by patients after operation can improve functional recovery,shorten healing time,relieve postoperative pain symptoms and it’s safe.However,due to the limitation of the quantity and quality included in the study,the above conclusion still need to be verified by more high-quality study.
作者
王少雄
李同荟
刘洋
郑盈盈
WANG Shao-Xiong;LI Tong-Hui;LIU Yang;ZHENG Ying-Ying(Prenatal Diagnosis Center,The Fourth Hospital of Shijiazhuang,Shijiazhuang050011,China;Department of Pharmacy,theThird Hospital of Hebei Medical University,Shijiazhuang050051,China)
出处
《中国药物经济学》
2019年第4期123-128,共6页
China Journal of Pharmaceutical Economics
